Sarepta Therapeutics Inc $ 118.33 -4.66 (-3.79%)
Volume:
1,416,921
Avg Vol (1m):
1,388,115
Market Cap $:
8.82 Bil
Enterprise Value $:
8.26 Bil
P/E (TTM):
0.00
P/B:
8.87
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 2.16 | ||
| Equity-to-Asset | 0.59 | ||
| Debt-to-Equity | 0.49 | ||
| Debt-to-EBITDA | -0.86 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 5.96 | ||
| Beneish M-Score | -2.1 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -120.91 | ||
| Net Margin % | -169.87 | ||
| ROE % | -60.63 | ||
| ROA % | -37.64 | ||
| ROC (Joel Greenblatt) % | -255.28 | ||
| 3-Year Revenue Growth Rate | 433.1 | ||
| 3-Year EBITDA Growth Rate | 1.8 | ||
| 3-Year EPS without NRI Growth Rate | -1.6 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 8.87 | ||
| PS Ratio | 23.39 | ||
| EV-to-EBIT | -13.98 | ||
| EV-to-EBITDA | -14.61 | ||
| EV-to-Revenue | 22.62 | ||
| Current Ratio | 6.31 | ||
| Quick Ratio | 5.54 | ||
| Days Inventory | 949.88 | ||
| Days Sales Outstanding | 67.24 | ||
| Days Payable | 552.32 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.9 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 8.96 | ||
| Price-to-Median-PS-Value | 0.89 | ||
| Earnings Yield (Greenblatt) % | -7.16 |